<unk>  is used as monotherapy or in combination with other drugs for the treatment of type 2 diabetes. It does not appear to decrease the risk of heart attacks or strokes. It increases the risk of hospitalization for heart failure by about 27%. Like other DPP-4 inhibitors, it has relatively modest HbA1c lowering ability, is associated with a relatively low risk of hypoglycemia, and does not cause weight gain.<unk>  improved mean HbA1c levels (relative to placebo) in a 24-week trial in people with type 2 diabetes. Combination therapy with<unk>  and metformin was more effective than<unk>  or metformin monotherapy. When the relative benefits of increasing the dose of a sulfonylurea or adding<unk>  were assessed in a study of 768 patients, combination treatments were shown to have a significantly greater impact on fasting blood glucose than increasing the tested glibenclamide dose alone.
Saxagliptin
Linagliptin
Sitagliptin
Vildagliptin
Liraglutide
Exenatide
Canagliflozin
Pioglitazone